Global Infectious Disease Diagnostics Market Report 2021-2026: Products (Reagents, Assays, Instrument), Test (Laboratory, POC), Technology (Immunodiagnostics, Microbiology, PCR, NGS, INAAT)

Dublin, June 23, 2021 (GLOBE NEWSWIRE) -- The "Infectious Disease Diagnostics Market by Product (Reagents, Assays, Instrument), Test (Laboratory, POC), Technology (Immunodiagnostics, Microbiology, PCR, NGS, INAAT), Disease (COVID-19, Hepatitis, HAI, HIV, Influenza), End User - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

The global infectious disease diagnostics market size is projected to reach USD 39.8 billion by 2026 from USD 28.1 billion in 2021, at a CAGR of 7.2% during the forecast period.

Market growth is driven by factors such as global prevalence of infectious diseases & onset of COVID-19 and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements. On the other hand, an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the coming years.

The reagents, kits, and consumables accounted for the highest growth rate in the infectious disease diagnostics market, by product & service, during the forecast period

The infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services. The reagents, kits, and consumables segment accounted for the highest growth rate in the infectious disease diagnostics market in 2020. The requirement of reagents, kits and consumables in large numbers compared to instruments is the main factor contributing to this segment's high growth rate. This segment's market growth can also be attributed to repeat purchases of reagents, kits, and consumables compared to instruments.

HAIs segment accounted for the highest CAGR

Based on the disease type, the infectious disease diagnostics market is segmented into COVID-19, HIV, HAIs, hepatitis, CT/NG, HPV, TB, influenza, and other infectious diseases. The increasing number of cases and the availability of many COVID-19 diagnostic tests are driving the growth of this market. In 2020, the HAIs segment accounted for the highest CAGR.

Diagnostic Laboratories segment accounted for the highest CAGR

Based on end-users, the infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users. In 2020, the diagnostic laboratories segment accounted for the highest CAGR. This can be attributed to increased test volume of infectious diseases and strengthening healthcare infrastructure for efficient disease diagnosis and treatment.

Asia Pacific: The fastest-growing region infections disease diagnostics market

The global infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Factors such as government efforts to increase awareness about the early detection of diseases and regular health check-ups, continuously rising healthcare expenditure, increasing number of hospitals, clinical diagnostic laboratories in India and China, and strengthening research base for diagnostic procedures across India, China, and Japan are driving the growth of the infectious disease diagnostics market in this region.

Premium Insights

• The Rising Adoption of Poc Diagnostics is Expected to Support Market Growth During the Forecast Period

• Reagents, Kits, and Consumables Segment to Command the Largest Share of the Market, by Product & Service, in 2021

• Immunodiagnostics to Hold the Largest Share of the Market During the Forecast Period

• Diagnostic Laboratories Dominate the End-User Market

Market Dynamics

Drivers

• Global Prevalence of Infectious Diseases and Onset of COVID-19

• Rising Focus on R&D and Funding in Infectious Disease Diagnostics

• Growing Awareness for Early Disease Diagnosis in Developing Countries

• Rising Technological Advancements in Infectious Disease Diagnostics

• Shift in Focus from Centralized Laboratories to Decentralized Poc Testing

Restraints

• Unfavorable Reimbursement Scenario

Opportunities

• Growth Opportunities in Growing Economies

Challenges

• Changing Regulatory Landscape

• Operational Barriers

• COVID-19 Impact Analysis

Pricing Analysis

• Pricing Analysis of Infectious Disease Diagnostic Products (2021)

Patent Analysis

• Polymerase Chain Reaction

• Immunodiagnostics

Value Chain Analysis

Supply Chain Analysis

Ecosystem Analysis

Porter's Five Forces Analysis

PESTLE Analysis

Regulatory Landscape

Trade Analysis

• Trade Analysis for Culture Media

Technology Analysis

Yc-Ycc Shift

List of Companies Profiled in the Report:

• Abbott Laboratories (US)

• F. Hoffmann-La Roche Ltd. (Switzerland)

• bioMerieux SA (France)

• Thermo Fisher Scientific Inc. (US)

• Danaher Corporation (US)

• QuidelCorporation(US)

• Hologic, Inc. (US)

• PerkinElmer Inc. (US)

• Bio-Rad Laboratories, Inc. (US)

• QIAGEN (Netherlands)

• Siemens Healthineers AG (Germany)

• Becton, Dickinson and Company (US)

• DiaSorin S.p.A (Italy)

• Grifols S.A. (Spain)

• Sysmex Corporation (Japan)

• Ortho Clinical Diagnostics (US)

• Genetic Signatures (Australia)

• Luminex Corporation (US)

• Meridian Bioscience (US)

• OraSure Technologies (US)

• Trinity Biotech Plc. (Ireland)

• Chembio Diagnostic Systems, Inc. (US)

• Seegene Inc. (South Korea)

• Co-Diagnostics, Inc. (US)

• ELITechGroup (France)

• Epitope Diagnostics, Inc. (US)

• Trivitron Healthcare (India)

• Meril Life Sciences Pvt. Ltd. (India)

• InBios International, Inc. (US)

• ABACUS Diagnostica Oy (Finland)

For more information about this report visit https://www.researchandmarkets.com/r/lwb7ce

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900